Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Target Raised at TD Cowen

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective upped by stock analysts at TD Cowen from $550.00 to $575.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the pharmaceutical company’s stock. TD Cowen‘s price target would suggest a potential upside of 7.10% from the company’s previous close.

A number of other research analysts have also recently commented on the stock. JPMorgan Chase & Co. initiated coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 11th. They issued an “overweight” rating and a $560.00 target price on the stock. Wells Fargo & Company lifted their price target on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a research report on Tuesday. Jefferies Financial Group boosted their price target on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, September 23rd. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Finally, The Goldman Sachs Group set a $653.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $588.56.

Vertex Pharmaceuticals Stock Down 2.9%

NASDAQ:VRTX traded down $16.27 on Tuesday, reaching $536.88. The company’s stock had a trading volume of 807,723 shares, compared to its average volume of 1,386,333. Vertex Pharmaceuticals has a 12-month low of $403.16 and a 12-month high of $568.67. The firm has a market cap of $136.26 billion, a price-to-earnings ratio of 31.20, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. The stock has a 50 day moving average price of $523.32 and a 200 day moving average price of $479.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.80 earnings per share. Equities research analysts expect that Vertex Pharmaceuticals will post 16.74 EPS for the current fiscal year.

Institutional Trading of Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of VRTX. United Advisor Group LLC increased its stake in shares of Vertex Pharmaceuticals by 17.4% during the 3rd quarter. United Advisor Group LLC now owns 633 shares of the pharmaceutical company’s stock worth $331,000 after purchasing an additional 94 shares in the last quarter. Plancorp LLC purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at approximately $254,000. May Hill Capital LLC lifted its stake in Vertex Pharmaceuticals by 4.2% in the 3rd quarter. May Hill Capital LLC now owns 643 shares of the pharmaceutical company’s stock valued at $336,000 after buying an additional 26 shares in the last quarter. Ashton Thomas Private Wealth LLC lifted its stake in Vertex Pharmaceuticals by 10.4% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,994 shares of the pharmaceutical company’s stock valued at $1,565,000 after buying an additional 281 shares in the last quarter. Finally, Calamos Wealth Management LLC grew its holdings in Vertex Pharmaceuticals by 13.0% during the 3rd quarter. Calamos Wealth Management LLC now owns 1,252 shares of the pharmaceutical company’s stock valued at $655,000 after buying an additional 144 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
• Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
• Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
• Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.